Please use this identifier to cite or link to this item: http://repositorio.unicamp.br/jspui/handle/REPOSIP/320425
Type: Artigo de Periódico
Title: Low Ten-eleven-translocation 2 (tet2) Transcript Level Is Independent Of Tet2 Mutation In Patients With Myeloid Neoplasms
Author: Scopim-Ribeiro
R; Machado-Neto
JA; Campos
PD; Niemann
FS; Lorand-Metze
I; Costa
FF; Saad
STO; Traina
F
Abstract: New sequencing technologies have enabled the identification of mutations in Ten-eleven-translocation 2 (TET2), an enzyme that catalyzes the conversion of 5-methylcytosine into 5-hydroxymethylcytosine (5-hmC) in myeloid neoplasms. We have recently identified reduced TET2 mRNA expression in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), which is associated with a poor overall survival in MDS. We herein aimed to investigate TET2 mutations and their impact on TET2 expression in a cohort of patients with myeloid neoplasms, including MDS and AML patients. Findings: TET2 mutations were observed in 8 out of 19 patients (42 %) with myeloid neoplasms. The TET2 expression profile was similar between in wild type and in TET2 mutated patients. Conclusion: Our results suggest that TET2 expression is reduced in MDS/AML patients, independently of mutational status.
Subject: Ten-eleven-translocation 2
Tet2
Mutation
Myelodysplastic Syndromes
Acute Myeloid Leukemia
Editor: BIOMED CENTRAL LTD
Rights: aberto
Identifier DOI: 10.1186/s13000-016-0476-4
Address: http://diagnosticpathology.biomedcentral.com.ez88.periodicos.capes.gov.br/articles/10.1186/s13000-016-0476-4
Date Issue: 2016
Appears in Collections:Unicamp - Artigos e Outros Documentos

Files in This Item:
File SizeFormat 
000372423800001.pdf638.84 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.